Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative phosphorylation (OXPHOS) induction as a profound metabolic alteration to confer KRAS-mutant non-small cell lung cancer...

Full description

Bibliographic Details
Main Authors: Juanjuan Feng, Zhengke Lian, Xinting Xia, Yue Lu, Kewen Hu, Yunpeng Zhang, Yanan Liu, Longmiao Hu, Kun Yuan, Zhenliang Sun, Xiufeng Pang
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Acta Pharmaceutica Sinica B
Subjects:
KRAS-mutant lung cancer
MEK inhibitors
Drug resistance
Metabolic rewiring
Mitochondrial oxidative phosphorylation
Pyruvate dehydrogenase complex
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522004488

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522004488

Similar Items